Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.2750 (3.43%) ($5.2750 - $5.2750) on Wed. Apr. 21, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.18% (three month average) | RSI | 61 | Latest Price | $5.2750(3.43%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 1.2% a day on average for past five trading days. | Weekly Trend | ADMS advances 2.9% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) EMHY(92%) IGOV(86%) HYG(34%) FXI(27%) MCHI(23%) | Factors Impacting ADMS price | ADMS will decline at least -2.59% in a week (0% probabilities). GLD(-20%) USO(-44%) IVW(-21%) IWF(-20%) QQQ(-24%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.59% (StdDev 5.18%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $5.16(2.23%) | 10 Day Moving Average | $4.92(7.22%) | 20 Day Moving Average | $4.93(7%) | To recent high | -20.8% | To recent low | 5.1% | Market Cap | $149m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |